Physician profile
Eric E Schmidt
NPI 1922007368
$290,281.77
in general payments reported to CMS, 2019-2025
35 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $29K · 2021: $35K · 2022: $59K · 2023: $14K · 2024: $51K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $11K · Food and Beverage: $8,738 · Honoraria: $4,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,175.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $30,125.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Travel and Lodging | $11,254.04 |
| Food and Beverage | $8,737.90 |
| Honoraria | $4,286.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $141,386.96 | 2019-2022 | |
| Abbvie INC. | $44,524.20 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $41,147.47 | 2022-2025 | Miebo, Xiidra, Infuse |
| Topcon Healthcare, INC. | $12,612.34 | 2023-2025 | |
| Harrow Eye, LLC | $10,155.82 | 2024-2025 | Vevye, Triesence |
| Aerie Pharmaceuticals, INC. | $6,003.50 | 2019-2021 | |
| Alcon Vision LLC | $5,034.14 | 2020-2025 | Rhopressa, Rocklatan, Precision 1 |
| Thea Pharma INC. | $4,493.69 | 2023-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $4,308.11 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $2,703.07 | 2019 | |
| Glaukos Corporation | $2,540.04 | 2023-2025 | Travoprost Intraocular Implant - Idose, Radius, Radius Xr |
| Heru, INC. | $2,500.00 | 2025 | Heru Hmd |
| Biotissue Holdings INC. | $2,250.82 | 2023-2024 | |
| Carl Zeiss Meditec, INC. | $1,834.53 | 2021-2025 | Forum, Iolmaster 700, Visumax |
| Kala Pharmaceuticals, INC. | $1,651.32 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $1,380.29 | 2021-2022 | |
| Tearlab Corp | $1,355.56 | 2023 | Tearlab Osmolarity System |
| Lumenis Be INC | $1,200.00 | 2022 | |
| Apellis Pharmaceuticals, INC. | $786.00 | 2024 | |
| Ivantis, INC | $675.00 | 2020 | |
| Topcon Corporation | $238.37 | 2024 | |
| Sight Sciences, INC. | $225.30 | 2020-2024 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $195.30 | 2020 | |
| Lkc Technologies, INC. | $175.82 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.50 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $167.59 | 2019-2025 | Bromsite, Cequa, Xelpros |
| Oyster Point Pharma, INC. | $133.19 | 2022-2024 | Ryzumvi, Tyrvaya |
| Coopervision INC. | $131.83 | 2019-2023 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $88.75 | 2020-2024 | Acuvue |
| Carl Zeiss Meditec USA, INC. | $68.05 | 2021 | |
| Topcon Healthcare Solutions, INC. | $51.65 | 2023 | |
| Mallinckrodt Hospital Products INC. | $26.33 | 2022 | |
| Notal Vision, INC. | $26.13 | 2025 | Foresee Home |
| Dompe US, INC. | $19.90 | 2019 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.